Literature DB >> 29606506

Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice.

Takafumi Hiramoto1, Li B Li1, Sarah E Funk1, Roli K Hirata1, David W Russell2.   

Abstract

X-linked severe combined immunodeficiency (X-SCID) has been successfully treated by hematopoietic stem cell (HSC) transduction with retroviral vectors expressing the interleukin-2 receptor subunit gamma gene (IL2RG), but several patients developed malignancies due to vector integration near cellular oncogenes. This adverse side effect could in principle be avoided by accurate IL2RG gene editing with a vector that does not contain a functional promoter or IL2RG gene. Here, we show that adeno-associated virus (AAV) gene editing vectors can insert a partial Il2rg cDNA at the endogenous Il2rg locus in X-SCID murine bone marrow cells and that these ex vivo-edited cells repopulate transplant recipients and produce CD4+ and CD8+ T cells. Circulating, edited lymphocytes increased over time and appeared in secondary transplant recipients, demonstrating successful editing in long-term repopulating cells. Random vector integration events were nearly undetectable, and malignant transformation of the transplanted cells was not observed. Similar editing frequencies were observed in human hematopoietic cells. Our results demonstrate that therapeutically relevant HSC gene editing can be achieved by AAV vectors in the absence of site-specific nucleases and suggest that this may be a safe and effective therapy for hematopoietic diseases where in vivo selection can increase edited cell numbers.
Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AAV vector; genome editing; hematopoietic stem cells

Mesh:

Substances:

Year:  2018        PMID: 29606506      PMCID: PMC5993949          DOI: 10.1016/j.ymthe.2018.02.028

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  59 in total

1.  Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy.

Authors:  M Otsu; S M Anderson; D M Bodine; J M Puck; J J O'Shea; F Candotti
Journal:  Mol Ther       Date:  2000-02       Impact factor: 11.454

Review 2.  New insights into the enigma of immunoglobulin D.

Authors:  Kang Chen; Andrea Cerutti
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

3.  Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells.

Authors:  V Stephan; V Wahn; F Le Deist; U Dirksen; B Broker; I Müller-Fleckenstein; G Horneff; H Schroten; A Fischer; G de Saint Basile
Journal:  N Engl J Med       Date:  1996-11-21       Impact factor: 91.245

4.  High-fidelity correction of mutations at multiple chromosomal positions by adeno-associated virus vectors.

Authors:  N Inoue; R K Hirata; D W Russell
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

5.  Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

Authors:  E A Rutledge; C L Halbert; D W Russell
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

6.  The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1.

Authors:  J M Puck; S M Deschênes; J C Porter; A S Dutra; C J Brown; H F Willard; P S Henthorn
Journal:  Hum Mol Genet       Date:  1993-08       Impact factor: 6.150

7.  Gene targeting in stem cells from individuals with osteogenesis imperfecta.

Authors:  Joel R Chamberlain; Ulrike Schwarze; Pei-Rong Wang; Roli K Hirata; Kurt D Hankenson; James M Pace; Robert A Underwood; Kit M Song; Michael Sussman; Peter H Byers; David W Russell
Journal:  Science       Date:  2004-02-20       Impact factor: 47.728

8.  Adeno-associated virus vectors integrate at chromosome breakage sites.

Authors:  Daniel G Miller; Lisa M Petek; David W Russell
Journal:  Nat Genet       Date:  2004-06-20       Impact factor: 38.330

9.  A genome-wide map of adeno-associated virus-mediated human gene targeting.

Authors:  David R Deyle; R Scott Hansen; Anda M Cornea; Li B Li; Amber A Burt; Ian E Alexander; Richard S Sandstrom; John A Stamatoyannopoulos; Chia-Lin Wei; David W Russell
Journal:  Nat Struct Mol Biol       Date:  2014-10-05       Impact factor: 15.369

10.  Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors.

Authors:  Jianbin Wang; Colin M Exline; Joshua J DeClercq; G Nicholas Llewellyn; Samuel B Hayward; Patrick Wai-Lun Li; David A Shivak; Richard T Surosky; Philip D Gregory; Michael C Holmes; Paula M Cannon
Journal:  Nat Biotechnol       Date:  2015-11-09       Impact factor: 54.908

View more
  7 in total

1.  AAV6 Is Superior to Clade F AAVs in Stimulating Homologous Recombination-Based Genome Editing in Human HSPCs.

Authors:  Amanda M Dudek; Matthew H Porteus
Journal:  Mol Ther       Date:  2019-09-12       Impact factor: 11.454

2.  CRISPR-READI: Efficient Generation of Knockin Mice by CRISPR RNP Electroporation and AAV Donor Infection.

Authors:  Sean Chen; Sabrina Sun; Dewi Moonen; Clancy Lee; Angus Yiu-Fai Lee; David V Schaffer; Lin He
Journal:  Cell Rep       Date:  2019-06-25       Impact factor: 9.423

3.  Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break.

Authors:  Geoffrey L Rogers; Hsu-Yu Chen; Heidy Morales; Paula M Cannon
Journal:  Mol Ther       Date:  2019-09-09       Impact factor: 11.454

Review 4.  The delivery challenge: fulfilling the promise of therapeutic genome editing.

Authors:  Joost van Haasteren; Jie Li; Olivia J Scheideler; Niren Murthy; David V Schaffer
Journal:  Nat Biotechnol       Date:  2020-06-29       Impact factor: 54.908

Review 5.  Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease.

Authors:  Elena Blanco; Natalia Izotova; Claire Booth; Adrian James Thrasher
Journal:  Front Immunol       Date:  2020-11-27       Impact factor: 7.561

Review 6.  The Role of Recombinant AAV in Precise Genome Editing.

Authors:  Swati Bijlani; Ka Ming Pang; Venkatesh Sivanandam; Amanpreet Singh; Saswati Chatterjee
Journal:  Front Genome Ed       Date:  2022-01-13

Review 7.  CRISPR/Cas systems usher in a new era of disease treatment and diagnosis.

Authors:  Ruiting Li; Qin Wang; Kaiqin She; Fang Lu; Yang Yang
Journal:  Mol Biomed       Date:  2022-10-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.